Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 proof-of-concept study of dapansutrile (OLT1177) capsules in acute gout flares
2016-000943-14Phase 2Completed
- Sponsor
- Olatec Therapeutics LLC
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of dapansutrile in gout, sponsored by Olatec Therapeutics LLC. Primary endpoint: Primary safety and tolerability endpoints. Started Dec 2016; status: completed.
02
Drugs
dapansutrile
03
Conditions
gout
Beyond the preview
Go deeper on 2016-000943-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000943-14.